A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity



Status:Recruiting
Healthy:No
Age Range:12 - Any
Updated:3/31/2019
Start Date:July 19, 2017
End Date:July 30, 2025
Contact:SARC Trials
Email:SARC@sarctrials.org
Phone:734-930-7600

Use our guide to learn which trials are right for you!

SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant
radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent
radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration
of pembrolizumab will be one year in the experimental arm.

This is a multicenter, randomized phase II trial with an initial safety run-in to test the
safety and efficacy of neoadjuvant pembrolizumab with image-guided radiotherapy and adjuvant
pembrolizumab compared to radiation therapy alone in patients with clinically localized
extremity soft tissue sarcoma at high risk for developing metastatic disease (tumor size > 5
cm, intermediate- to high-grade; approximately 50% risk for distant disease at 2 years).
Histologies will be limited to undifferentiated pleomorphic sarcoma and
dedifferentiated/pleomorphic liposarcoma based on preliminary data from SARC028. Other terms
for undifferentiated pleomorphic sarcoma may include, but are not limited to. pleomorphic
undifferentiated sarcoma, unclassified spindle cell sarcoma, spindle cell sarcoma not
otherwise specified, pleomorphic spindle cell sarcoma, pleomorphic fibroblastic sarcoma,
undifferentiated high-grade pleomorphic sarcoma, pleomorphicsarcoma with prominent
inflammation, pleomorphic sarcoma with giant cells, malignant fibrous histiocytoma (including
storiform-pleomorphic and inflammatory subtypes), fibrosarcoma, and myxofibrosarcoma (located
deep to the fascia in muscle). Radiation therapy with three cycles of pembrolizumab will be
administered as neoadjuvant therapy for patients randomized to the experimental arm. These
patients will also receive up to fourteen cycles of adjuvant pembrolizumab after surgical
resection. Patients in the standard of care arm will receive neoadjuvant radiotherapy (50 Gy
in 25 fractions) followed by surgical resection as in RTOG 0630.

Inclusion Criteria:

- Age ≥ 12 years

- Histologically confirmed diagnosis of grade 2 or 3 out of 3 UPS or
dedifferentiated/pleomorphic LPS of the extremity (including limb girdle, i.e.
shoulder or hip) that measures greater than 5 cm in any direction as assessed by
imaging; Alternative terms for UPS meeting inclusion criteria include but are not
limited to the following

- Patients with non-melanomatous skin cancer, in situ carcinoma, or low-risk prostate
cancer can be enrolled.

- ECOG Performance Status of 0 or 1

- Resectable primary tumor with no evidence of metastatic disease by imaging. Imaging
must be performed within 45 days of Day 1 of study.

- Adequate organ function within 10 days of Day 1

- Written, voluntary informed consent

- Fertile men and women of childbearing potential must agree to use an effective method
of birth control from Day 1 of study and for 120 days after last pembrolizumab
administration in both sexes. Women of childbearing potential include pre-menopausal
women and women within the first 2 years of the onset of menopause. Women of
childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1
of study.

Exclusion Criteria:

- Prior chemotherapy, targeted small molecule therapy, or radiation therapy for current
diagnosis of sarcoma

- Prior radiation therapy in excess of 20 Gy to the site of the current diagnosis of
sarcoma. No overlap with prior radiation fields in excess of 20 Gy is allowed.

- Concurrent, clinically significant, active malignancies within two years of study
enrollment.

- Patients with locally recurrent sarcoma after surgery alone are eligible for
enrollment if other inclusion criteria are met.

- Patients with severe and/or uncontrolled concurrent medical disease that in the
opinion of the investigator could cause unacceptable safety risks or compromise
compliance with the protocol

- Major surgery within three months prior to Day 1 of study or who have not recovered
adequately from prior surgery.

- Currently receiving a study therapy or if they had an investigational agent within 4
weeks at the time of enrollment.

- Women who are pregnant or nursing/breastfeeding, or expecting to conceive or men who
are expecting to father children within the projected duration of the trial, starting
with the pre-screening or screening visit through 120 days after the last dose of
pembrolizumab.

- Inability to comply with protocol required procedures

- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
form of immunosuppressive therapy by oral or IV routes within 7 days prior to the
first dose of trial treatment

- Known history of active TB (Bacillus Tuberculosis)

- Hypersensitivity to pembrolizumab or any of its excipients

- Metastatic disease or regional lymph node involvement. Chest CT will be mandatory
prior to enrollment to evaluate for the presence of metastatic disease. Pulmonary
nodule(s) < 5 mm without a histological diagnosis may not be the basis for study
exclusion given the lack of specificity of chest CT. If pulmonary nodule(s) > 5 mm are
noted on chest CT but appear stable relative to prior chest imaging of at least 6
months duration, then this is permitted.

- Unresectable disease or medically inoperable

- Planned to receive neoadjuvant or adjuvant chemotherapy for current diagnosis of
localized soft tissue sarcoma

- Active autoimmune disease that has required systemic treatment in the past two years
(i.e. with use of disease modifying agents, systemic corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment.

- Has a history of (non-infectious) pneumonitis that required systemic steroids or
current pneumonitis.

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial

- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

- Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)

- Known active Hepatitis B (e.g., HBsAg reactive, confirmed by detectable viral load) or
Hepatitis C (e.g., HCV RNA [qualitative] detected)

- Received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.

- Diagnosis of scleroderma.

- Diagnosis of inflammatory bowel disease (Crohn's disease or Ulcerative Colitis).
We found this trial at
14
sites
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Phone: 919-681-1883
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
(617) 724-4000
Massachusetts General Hospital Cancer Center An integral part of one of the world
?
mi
from
Boston, MA
Click here to add this to my saved trials
Camperdown, New South Wales
?
mi
from
Camperdown,
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials